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1. Introduction
1.1. Overview of prostate cancer and standard treatments
The estimated number of new prostate cancer cases for 2011 was 240,890. The majority of
diagnosed prostate cancers (PCa) is found early due to the widespread use of the screening
test for prostate specific antigen (PSA) and are considered low risk [1]. The prognosis for
men diagnosed with low-risk prostate cancer is good and the NIH is recommending active
surveillance [1]. Active surveillance has the benefit of reducing treatment side effects, in‐
cluding erectile dysfunction and incontinence, for men that are unlikely to die from their
cancer [2]. Locally advanced prostate cancers are higher risk, and a substantial fraction of
these patients will eventually die of the disease, though median survival may be as long as 5
years. If prostate cancer has spread to distant organs, current therapy will inevitably fail [3].
Because the androgen receptor (AR) is important for prostate cancer development and pro‐
gression, androgen deprivation therapy (ADT), which either reduces the production of an‐
drogens by surgical or medical castration, or interferes with AR function via the use of anti-
androgens, is increasingly becoming a central component in the management of metastatic
prostate cancer [3]. ADT initially leads to improved clinical outcomes in about 90% of the
cases. However, most tumors become androgen independent (AI) and no longer respond to
standard hormonal therapies, chemotherapeutics or radiotherapy [3]. Thus, improved thera‐
peutic strategies that target key pathways and molecules are essential to improve the out‐
come for patients with AI prostate cancer (AIPC). Interestingly, recent data shows that the
AR pathway is often still engaged in AIPC, possibly due to receptor promiscuity or hyper‐
sensitivity. Therefore, some scientists believe that a strategy of targeting AR expression, ei‐
© 2013 Davis et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
ther directly or indirectly, may be helpful in these cases [4]. Indeed, elegant methods
employing genome wide analysis are being used to identify small molecule antagonists of
AR function [5]. Other ideas for targeted therapies include small molecule inhibition of met‐
abolic enzymes such as fatty acid synthase (FASN) because cancer cells, unlike their normal
counterparts, synthesize de novo large quantities of fatty acids and cholesterol [6] and inhib‐
itors of vascular endothelial growth factor receptor (VEGFR) to suppress vascularization [7].
2. Non-androgen regulated transcription factors in prostate cancer;
rationale for targeting
Most targeted small molecule therapies under development interfere with the function of re‐
ceptors on the cell surface or kinases located in the cytoplasm. Transcription factors have
been underutilized as targets of cancer therapeutics, the exceptions being the steroid hor‐
mone receptors, such as the AR, and nuclear factor kappa B (NF-฀B) [8, 9]. However, it is
imperative to identify novel targets for the design of molecular treatments for cancers, in‐
cluding AIPC. Advances in drug delivery systems and a better understanding of how tran‐
scription factors act should overcome issues with targeting this important group of proteins.
Thus, we believe that effective therapeutics for AIPC can be developed by identifying and
targeting key transcriptional regulators, other than the AR, that are required for prostate
cancer proliferation and survival. To identify potential targets that are master transcriptional
regulators, one looks for DNA binding proteins whose activity is required for cell fate deci‐
sions, stem cell homeostasis, proliferation, and development. The regulatory roles played by
Core Binding Factor (CBF) [10] and CBF1, Suppressor of Hairless, Lag-1 (CSL), the down‐
stream effector of Notch receptors, place these transcription factors at the pinnacle of signal‐
ing cascades required for malignancy [11, 12]. Perhaps not surprisingly, these two pathways
are genetically linked and exhibit cross talk. For example, enforced expression of RUNX1
rescues the Notch1-null phenotype in zebrafish [13] and in Notch1-null mice RUNX1 ex‐
pression is greatly reduced [14]. Moreover, Notch and RUNX1 cooperate during T-cell speci‐
fication in mammals and CBF is required for pre-thymic cells response to Notch signaling
[15]. Thus, these two important transcriptional pathways are linked and, together, present a
number of novel targets for the development of cancer therapies.
3. Core binding factor
More than twenty years ago, Nancy Speck and David Baltimore identified a DNA binding
activity that bound to the core site (TGTGGTAA) in the enhancer of Moloney Murine Leuke‐
mia Virus that, when mutated, altered disease specificity to produce thymic leukemia in‐
stead of erythroleukemia [16, 17]. This DNA binding activity, which was named Core
Binding Factor, was identified in a variety of cell lines [16]. Dr. Speck's laboratory purified
several peptides that had core- binding activity from calf thymus nuclei [18]. The Speck lab‐
oratory then went on to sequence 5 peptides and used these sequences to isolate 3 cDNA
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clones from a murine thymus library that encoded the three mammalian isoforms of CBFβ
(CBFβ p22.0, CBFβ p21.5, and CBFβ p17.6). [19]. The Speck study demonstrated that CBFβ
did not bind to DNA itself but, instead, partnered with a DNA binding protein, at that time
termed acute myeloid leukemia-1 (AML-1), since one of their peptides appeared to be con‐
tained in the bovine homologue of the human AML-1. AML-1 had been identified by virtue
of its involvement in the t(8;21) chromosomal translocation in 1991 [20]. A similar DNA
binding activity was also isolated via interaction with the polyomavirus enhancer and was
called polyomavirus enhancer binding protein 2 (PEBP2) [21]. CBF also binds to the Type B
leukemogenic virus enhancer [22]. In 1993, Scott Hiebert’s laboratory demonstrated that
AML-1 selected a site related to the enhancer core motif (TGT/cGGT) and identified the
DNA binding domain [23]. Later, Dr. Hiebert’s group identified a larger isoform of AML-1
(termed AML-1B) produced from the AML-1 gene using a homology screen of a human B-
cell library [24]. Two other AML-1 family members expressed from independent genes were
identified; AML-2 and AML-3 [25]. Following these studies, the AML-1 family of proteins
underwent a revision in nomenclature with guidance from the Human Genome Organiza‐
tion [26]. AML-1 is now termed RUNX1, AML-2 is now termed RUNX3, and AML-3 is now
termed RUNX2. The murine nomenclature is written in small case. This nomenclature will
be used for the remainder of the chapter.
Mammalian CBF is a heterodimeric complex consisting of RUNX1, RUNX2, or RUNX3. As
the Speck laboratory suggested, these three proteins bind to promoters and enhancers of tar‐
get genes (or viral LTRs) as a heterodimer with CBFβ [10, 27]. DNA binding is achieved with
a central domain (runt domain), consisting of an S-type immunoglobulin fold resembling
the DNA binding domains of p53 and NF-kB [23, 28]. Although CBFβ does not contact DNA
it regulates and enhances RUNX protein DNA binding via interactions with the Runt do‐
main [28]. Complexity in CBF-regulated transcription comes about not only through co-ex‐
pression in many tissues and a highly conserved DNA binding domain and recognition
sequence, but also through the existence of multiple isoforms. For example, the RUNX1
gene produces three main isoforms, all of which contain the DNA binding domain. These
isoforms are thought to have both overlapping and unique functions. For example, RUNX1
isoforms are differentially expressed during hematopoietic differentiation of human embry‐
onic stem cells (ESCs) and the RUNX1c isoform is expressed at the time of emergence of de‐
finitive HSCs [29]. Such complexity makes it difficult to assign function to each RUNX
isoform and clearly, we are just at the beginning of understanding the distinct roles played
by each protein. CBFβ is encoded on one gene in mammals but, as noted above, multiple
isoforms are produced that may have distinct functions [19].
CBF is conserved in all multicellular organisms examined but is not present in yeast or any
nonmetazoan studied to date. RUNX and CBFβ genes were identified in the nematode C.
elegans, the fruit fly Drosophila melanogaster, which contains two CBFβ genes and four RUNX
genes, the sea urchin (Strongylocentrotus purpuratus), sponges, puffer fish (Takifugu rubripes),
and the zebrafish (Danio rerio) [30-32]. In Drosophila, RUNT, the first RUNX gene identified
in that organism, is required for segmentation [33]. RUNT gene mutations produce fly em‐
bryos with segmentation defects while Lozenge, a second RUNX gene in fruit flies, is re‐
quired for eye development (Coffman 2009). In sea urchin, the spRunt-1 gene is required
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throughout development for cellular proliferation, cell survival, and tissue-specific gene ex‐
pression [30]. Unlike mammals, two CBFβ homologs exist in Drosophila. Big brother and
Brother (Bgb and Bro) display high homology to human CBFβ and are required for RUNX
gene function in flies [34]. Studies in these model organisms have clearly demonstrated that
CBF coordinates cellular proliferation, stem cell fate and terminal differentiation [30, 35].
Mouse genetics further demonstrate specific requirements for CBF in development and stem
cell function. For example, RUNX1 is required for hematopoietic development and Runx1
null animals die in utero by day E12.5 due to a complete absence of fetal-liver derived hema‐
topoiesis [36]. Runx2 is critical for skeletal morphogenesis and Runx2 null mice survive until
birth but die shortly thereafter due to a complete lack of bone formation [37]. Interestingly,
Runx1 and Runx3 are also expressed in bone cells and support skeletal development [27,
38]. Runx3 null mice were reported to display gut hyperplasia due to an increase in cell pro‐
liferation and a reduced rate of apoptosis [39]. However, a second study showed that
Runx3-deficient mice develop severe limb ataxia due to a defect in the dorsal root ganglion
(DRG) proprioceptive neurons [40]. Runx3 is also important for hematopoiesis [27, 41]. Simi‐
lar genetic studies demonstrated that CBFβ is required for RUNX protein function. For ex‐
ample, CBFβ knockdown mice recapitulate the Runx1 null phenotype and hematopoietic-
specific rescue of CBFβ null animals has demonstrated that CBFβ, like Runx2, is required for
skeletal development [42, 43]. Thus, CBF functions as a master regulator of genes required
for development, differentiation and stem cell maintenance [44, 45]. The requirement for
CBFβ is likely due to it’s ability to enhance RUNX DNA binding and, therefore, to augment
the transcriptional strength of the RUNX factors [46].
4. Cancers associated with alterations to CBF
Alterations to CBF activity result in human disease. For example, human RUNX1 was first
identified as the target of the t(8;21) chromosomal translocation associated with acute mye‐
logenous leukemia (AML) [20, 47]. The t(8;21) is associated with approximately 12% of AML
cases [48]. The t(8;21) results in the production of a chimeric transcription factor that retains
the RUNX1 (chromosome 21) DNA binding domain but replaces the entire C-terminus with
MTG8 (also called ETO), a transcriptional co-repressor [24, 49, 50]. RUNX1 is also the target
of the rarer t(16;21) found in both de novo and therapy-related AML [51] and the t(12;21)
identified in pre-B-cell acute lymphoblastic leukemia (ALL) [52]. These translocations fuse
the RUNX1 DNA binding domain to an ETO-related protein termed MTG16 (CBFA2T3) and
to an ETS-related transcription factor, respectively, to create chimeric gene regulatory fac‐
tors [51, 52]. CBFβ is also targeted by genomic abnormalities that lead to AML. For example,
the pericentric inversion of chromosome 16 produces a chimeric CBFβ/smooth muscle myo‐
sin heavy chain (SMMHC) protein termed CBFβ–SMMHC [53]. These chimeric transcription
factors are thought to contribute to leukemogenesis by interfering with CBF-regulated tran‐
scription [54]. Moreover, these chromosomal abnormalities demonstrate that CBF alterations
can result in both lymphoid and myeloid leukemias.
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CBF’s role in blood development and in leukemia was brought into sharp focus by animal
studies and by the identification of the molecular defects associated with AML. For many
years, RUNX1 was considered blood specific, in part because of the strong phenotype ob‐
tained in Runx1-null mice. More recently, the expression, composition and function of CBF
was studied in a wide variety of normal and cancerous cell lines and tissues. For example,
RUNX protein expression was identified in the hair follicle stem cells (HFSCs) of the skin,
and CBF is required to regulate HFSC proliferation [55]. Moreover, RUNX1 expression is ac‐
tivated in a chemical-induced model of rodent skin squamous cell carcinoma [55].
The expression of RUNX factors in prostate epithelial cell lines and normal prostate tissue
was identified by real-time RT-PCR [56]. RUNX1, RUNX2, and RUNX3 were variously ex‐
pressed in normal prostate tissue, an immortalized, non-transformed cell line, prostate can‐
cer cell lines and primary prostate cancers [56]. To confirm that mRNA expression led to
active DNA binding activity, CBF presence was confirmed using electrophoretic mobility
shift assay (EMSA) [56]. While RUNX1 and RUNX2 were always expressed in prostate can‐
cer cell lines, RUNX3 expression was not observed in most prostate cancer cell lines [56].
This correlates well with other studies that have identified RUNX2 expression in prostate
cancer cell lines and showed that decreasing RUNX2 expression inhibits cell growth [57].
RUNX2 may play a role in tumor spread since RUNX2 triggers expression of bone-specific
genes in prostate cancers, which may be involved in bone metastasis [58, 59]. Moreover, in a
PTEN-deleted mouse model of prostate cancer, developing tumors increased Runx2 expres‐
sion [60]. Thus, there is evidence that Runx2 expression is increased in malignant versus be‐
nign prostate tissue and is associated with tumor metastasis [61]. Interestingly, in a study of
314 patients with clinically localized prostate cancer that were treated with radical prostatec‐
tomy, the allelic variant RUNX1 rs2253319 was associated with metastasis to lymph nodes
[62]. These data illustrate both the complexity of CBF expression in prostate and the involve‐
ment of CBF in cancer growth and metastasis. CBF is also highly expressed or altered in
lung, endometrioid, and breast cancers [63-65].
CBF interacts with steroid hormones in various tissues. For example, the vitamin D receptor
(VDR) associates with RUNX2 to regulate osteocalcin gene expression [66] and inappropri‐
ate expression of osteocalcin in prostate cancer cells depends upon RUNX2 [38]. CBF also
interacts with the androgen receptor. RUNX1 and RUNX2 have both been shown to activate
transcription from the prostate specific antigen (PSA) promoter and RUNX1 and RUNX2
physically associate with the AR [56] [57]. In prostate cancer cell lines, RUNX2 enhances
TGF-β and androgen response [57]. Thus, the CBF and AR transcriptional pathways inter‐
sect in a way that enhances AR signaling. These data suggest that targeting CBF in prostate
tumors should negatively impact AR signaling as well.
5. CBF inhibitors
Given that CBF and the AR pathways intersect and that CBF has been shown to regulate
gene expression changes associated with tumorigenesis and metastasis in prostate cancer
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cell  lines,  it  seems reasonable to identify small  molecules that  can inhibit  CBF function.
Small molecules that interfere with the interaction between the RUNX proteins and CBFβ
were recently described. In the first of these studies, the 3D structure of CBFβ was solved
using NMR and the RUNX1 binding interface was determined [67]. This information was
then used to perform a virtual chemical screen and using that information, allosteric in‐
hibitors of CBFβ were identified. The most potent inhibitor,  “17”,  inhibited proliferation
of the ME-1 cell line, a line derived from a patient with acute myelomonocytic leukemia
containing the inv(16),  by about 40% and showed very little cytotoxicity [67].  Treatment
of  cells  with  100  μm  concentrations  of  Inhibitor  17  reduced  RUNX1  DNA  binding  by
about 30%. Thus, compound 17 binds to a site removed from the heterodimerization in‐
terface and produces moderate changes in CBF DNA binding and cellular  proliferation.
These data suggest that allosteric inhibitors of protein complex formation could be useful
for probing CBF’s role in cancer.
A recent approach to identify a role for CBF in prostate and ovarian cancer provides com‐
pelling evidence that CBF is a druggable target. Davis and co-workers showed that CBFβ -
specific shRNAs inhibited the malignant phenotype of prostate and ovarian cancer cell lines
[68]. Cell lines displaying 70% reduction in CBFβ were unable to grow in an anchorage inde‐
pendent manner and did not form xenograft tumors in mice. Gene array data (Agilent
whole genome array) gathered during this study suggested that CBF-mediated gene expres‐
sion was inhibited. Bioinformatic searches for RUNX DNA binding sites in the promoter re‐
gions of the differentially expressed genes revealed that of the 200 genes that exhibited
altered expression, over 20% contained multiple putative RUNX binding sites (analyzed us‐
ing the consensus TGT/CGGT) within their upstream regulatory regions [68]. EMSA was
used to confirm a loss in CBF DNA binding activity [68]. These data clearly demonstrate
that inhibition of CBFβ expression leads to a reduction in CBF activity and that CBF activity
is required for the transformed phenotype.
The DNA binding activity of recombinant CBF is amenable to high throughput screening
(HTS) assays and a recent screen of the NIH Clinical Collection Library has identified com‐
pounds that inhibit CBF (Davis and Meyers, unpublished data). The CBFβ siRNAs and com‐
pounds identified via HTS or virtual screens show promise as tools for discovery and as
molecules that can be further developed into small molecule therapeutics in prostate cancer.
6. The Notch pathway
Notch gene mutations were first discovered in Drosophila  via malformations of the wing
[69]. This ligand-activated signaling pathway is a highly conserved mechanism for main‐
taining stem cell  function and regulating apoptosis,  proliferation and cell  fate  specifica‐
tion [69].  Mammals express four Notch receptor family members, termed Notch 1-4 and
five  ligands;  two  Jagged  family  ligands  (jagged-1  and  jagged-2)  and  three  delta-like  li‐
gands (Dll1, Dll3 and Dll4) [69]. The Notch receptors are highly similar in structure and
the  extracellular  domains  contain  epidermal  growth  factor-like  repeats.  The  Notch  li‐
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gands  are  also  transmembrane  proteins.  Thus,  the  Notch  receptors  regulate  cell  behav‐
ior  via  juxatacrine  signaling  that  requires  direct  contact  between  the  ligand-expressing
cells  and  those  cells  expressing  the  receptor.  Ligand  binding  activates  two  consecutive
proteolytic  cleavages  to  free  the  intracellular  portion  of  the  receptor,  which  is  referred
to as the Notch intracellular domain (NICD) [70]. The first cleavage is carried out by an
A Disintegrin  And Metalloprotease  (ADAM)-family  of  transmembrane metalloproteases.
The  second cleavage  is  carried  out  by  γ-secretase,  an  integral  membrane  enzyme com‐
plex,  that  is  perhaps  best  known  for  its  role  in  generating  the  amyloid-beta  peptide
found  in  brains  of  Alzheimer's  disease  patients  [70,  71].  The  NICD  is  a  transcriptional
co-activator. Once released, it travels to the nucleus via a nuclear transport signal where
it  binds  to  DNA-bound CSL.  NICD binding  to  CSL displaces  repressor  complexes  and
recruits the mastermind family (MAML, mastermind like) of transcriptional coactivators,
thereby  activating  the  transcription  of  Notch-responsive  genes  [69].  In  the  absence  of
Notch receptor activation, CSL nucleates transcriptional repressive complexes via recruit‐
ment  of  histone  deacetylase  activities  through  interaction  with  SHARP  (SMART  and
HDAC  associated  repressor)  and  corepressors  like  SMART/NcoR,  CtIP/CtBP  or  ETO
family  members  [72].  Interestingly,  ETO  (also  called  MTG8)  is  the  target  of  the  t(8;21)
that  produces  a  RUNX1/ETO fusion  gene.  Thus,  the  t(8;21)  targets  components  of  both
the  CBF  and  Notch  pathways,  highlighting  yet  another  way  in  which  these  pathways
intersect.
To date, a limited number of Notch-responsive genes have been identified. Some of the first
gene targets identified include the transcription factors Hairy and enhancer of split-1 (Hes1)
and Hairy and enhancer-of-split related with YRPW motif 1 (Hey1). Both Hes1 and Hey1
can be activated by a constitutively activated Notch1 receptor suggesting that these genes
are bona fide targets [69]. Other CSL target genes are important mediators of signaling, in‐
cluding Akt and NF-κB, and important cell cycle regulators such as c-myc, D-type cyclins,
p21Waf1/Cip1 and p53 [69]. CSL is the only down-stream transcription factor directly responsive
to Notch activation and, therefore, is crucial to Notch function.
The Notch pathway is deregulated in a variety of leukemias and solid cancers. For example,
the mammalian orthologue of Notch was identified as TAN1 the target of the t(7;9)
(q34;q34.4) in T-cell acute lymphocytic leukemia (T-ALL). While the t(7;9) is relatively rare
(1% of all T-ALL) [73], the Notch1 receptor is constitutively activated by point mutations in
the majority of T-ALL (almost 60%) [74]. Subsequent to the identification of Notch altera‐
tions in T-cell leukemia, the Notch pathway has been implicated in a variety of other human
malignancies including cancers of the breast, ovarian, prostate, colorectal, and pancreas, as
well as other leukemias [75-78]. In breast cancer, the Notch pathway components are com‐
monly over-expressed and increased expression of Notch or Jag1 correlates with poor prog‐
nosis [76]. More recently, some studies suggest that breast cancer stem cell fate is regulated
through the Notch pathway [79]. The Notch pathway is required for normal development of
the murine prostate, and like breast cancers, prostate cancers also utilize the Notch pathway
[80]. For example, Notch-1 and Jagged-1 expression constitute part of a gene expression sig‐
nature for prostate cancer [81]. Other evidence indicating a role for Notch signaling in pros‐
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tate cancer includes studies showing that Jagged-1 expression correlates with prostate
cancer recurrence and proliferation of prostate cancer cell lines [82, 83]. Moreover, down-
regulation of both Notch-1 and Jagged-1 expression in the androgen insensitive prostate
cancer cell line, PC3, was associated with a loss of malignancy and a reduction in Akt,
mTOR and NF-κB activation [84].
As discussed above, the constitutive activation of Notch receptor signaling in diverse can‐
cers is well documented, but the contribution of CSL to Notch-dependent oncogenesis has
not been well studied. Our recent publication was the first to demonstrate that CSL was es‐
sential for the growth of prostate and breast cancer derived cell lines [85]. In these cancer
cells, where Notch signaling is constitutive, CSL is required for growth in vitro. Thus, CSL is
not only the focal point of Notch-dependent transcriptional control but appears to be central
to the oncogenic Notch pathway as well [85].
In addition to the oncogenic functions associated with Notch signaling, the Notch pathway
can also be tumor suppressive in cells or tissues where Notch predominately promotes dif‐
ferentiation [86]. Notch associated tumor suppressor activity is best illustrated in carcinoma
of the skin, where keratinocyte specific inactivation of Notch1, Delta-like 1 (Dl1) or γ-secre‐
tase treatment accentuates tumor formation in chemical carcinogenesis models [87]. Increas‐
ingly, tumor suppressive activities of the Notch pathway are being reported, as interest in
Notch signaling and the use of γ-secretase inhibitors to block Notch receptor activation has
expanded. Inactivating mutations of Notch1 have been identified in head and neck squa‐
mous cell carcinoma [88] and haploinsufficiency of Notch1 or inhibition of Notch signaling
with monoclonal antibodies to the Notch ligand Delta-like 4 induces vascular tumors in
model systems [89]. As if to highlight the context dependent nature of Notch signaling, one
report provided evidence that activated Notch1 alleles cooperated with oncogenic Ras to in‐
duce pancreatic cancer while a second report indicated that inactivation of Notch1 cooperat‐
ed with Ras pathways in pancreatic cancers [90, 91]. This duality of function associated with
Notch signaling has led to serious concerns regarding Notch receptor activation as a target
of therapeutic intervention [86].
In prostate cancer, like in other cancers discussed above, Notch pathway signaling can be
tumor suppressive. For example, NICD activity and Hes1 expression have been observed
to  be  high  in  benign  prostatic  hyperplasia  but  low  in  prostate  cancer  indicating  that
Notch pathway activation can be lost during malignant transformation. Additionally, acti‐
vation  of  the  Notch  pathway  in  the  androgen  independent  prostate  cancer  cell  line,
DU145, inhibited cell growth and resulted in the activation of the PTEN tumor suppres‐
sor. Interestingly, knockdown of CSL in the DU145 cell line results in loss of cell growth
(Yong  and  Davis,  unpublished  data).  These  data  demonstrate  that  CSL  (in  a  repressed
complex) is required in cells where the Notch pathway can display tumor-suppressing ac‐
tivity. Clearly, the activity of the Notch pathway in prostate cancer is context dependent
and complex.
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7. Notch pathway inhibitors
Regardless of the data implicating the Notch pathway in tumor suppression as well as onco‐
genesis, chemotherapeutic targeting of the Notch pathway employing γ-secretase inhibitors
(GSI) to block release of the NICD has generated much interest [92]. GSIs, which were de‐
signed primarily for Alzheimer’s disease, developed by Merck, Novartis, Pfizer and Roche
are currently in clinical trials for a number of malignancies including T-ALL, lymphoma,
breast, colorectal, brain, pancreatic, and non-small cell lung carcinoma. However, targeting
the Notch pathway through the use of GSIs is problematic. Preclinical studies examining
GSI function in vitro are difficult because, with the notable exception of GSI-1, these drugs
do not display strong inhibitory effects on cell growth or survival in vitro. Also, while these
drugs do inhibit Notch signaling, they display poor specificity. As an example, the inhibi‐
tion of survival of breast carcinoma cell lines by GSI-1 was associated with inhibition of the
proteosome and not effects on Notch signaling [93]. In addition to off-target effects, Notch
inhibition by GSI has adverse effects on the intestinal system and immune function [94].
Lastly, as discussed above, the cell context determines whether the Notch pathway is onco‐
genic or tumor suppressive even within cancers of the same organ [86]. Thus, the conse‐
quence of inhibition of Notch receptor activation by GSI or inhibitory antibodies to Notch
receptors/ligands is difficult to predict.
Inhibition of Notch activation by GSIs, inhibitory antibodies that bind DSL ligands, or other
inhibitors of receptor activation target only the Notch activated state and they are less than
ideal. However, the Notch pathway is central to oncogenesis, and this idea fuels the search
for novel ways to inhibit the Notch signaling pathway [11]. Recently, the Bradner laboratory
developed a stabilized peptide that mimics MAML and binds to the NICD-CSL complex to
block interaction with endogenous MAML [95]. SAHM1, a 16 amino acid peptide which
blocks MAML binding to the NICD-CSL complex is cell-permeable and lowers NOTCH-tar‐
get gene expression when added to cells in culture [95]. SAHM1 lowers proliferation of T-
ALL cell lines suggesting that these small molecules will be useful as probes to dissect the
requirement for MAML in Notch signaling and as building blocks for a new generation of
Notch inhibitors.
Davis and co-workers tested the idea that direct inhibition of CSL would not only abrogate
Notch pathways in the activated oncogenic state, but also disrupt the transcriptional regula‐
tion of Notch pathway genes that are repressed in the Notch quiescent state [85]. According
to this argument, in cells or tissues where Notch activation is tumor suppressive, inhibition
of CSL would release the strong transcriptional repressive complexes positioned on Notch
targets. Removal of CSL-dependent repressive complexes could mimic the tumor suppres‐
sive activity of the Notch pathway. Indeed, Davis and co-workers addressed the role of CSL
in Notch-dependent signaling in prostate cancer cell lines, using lentiviral mediated transfer
of shRNA specific for CSL to knockdown expression of CSL. CSL knockdown was tracked
by EMSA and expression of the Notch pathway genes was documented using RT-PCR array
profiling. Knockdown of CSL expression produced gene expression changes distinct from
those induced by GSI inhibition of Notch signaling [85]. For example, inhibition of Notch
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receptor activation by DAPT resulted in repression of Hes1, a well-characterized CSL target
in prostate and breast cancer cell lines. In contrast, Hes1 mRNA levels were unaffected by
CSL ablation in prostate cancer cell lines, indicating that Hes1 expression does not require
the activating function of CSL [85]. Thus, Notch pathway-dependent transcriptional regula‐
tion of Hes1 is primarily through repression and ablation of CSL partially mimics Notch re‐
ceptor activation. While HES1 expression was not significantly altered by CSL knockdown,
the expression of other Notch pathway genes did change. One such gene, DTX1 is thought
to regulate Notch signaling either by targeting the NICD for ubiquitination and degradation
or by altering NICD transcriptional functions, possibly by competing for co-activators [96].
Davis and coworkers failed to generate stable cell lines after infection with the CSL-specific
shRNA but not with the control non-target (NT) shRNA. CSL knockdown cells were poorly
attached and growth inhibited as compared to the NT infected cells [96]. These data provide
strong evidence that CSL, the major Notch pathway effector, is required for cell growth in
prostate cancer cells lines, and suggest that CSL is an important candidate for small mole‐
cule therapies in AIPC.
8. Summary and future directions
Although the AR is an important target of therapeutics in the struggle against prostate can‐
cer, it remains imperative to develop effective strategies to target other important transcirp‐
tion pathways, especially in AIPC. To alter gene transcription, some scientists, for example,
are developing histone acetyl transferase inhibitors [97]. However, any such therapeutic
would be expected to lack specificity for particular oncogenic pathways. DNA binding tran‐
scription factors represent druggable targets that should produce a more specific outcome,
and are under appreciated as targets of small molecule inhibitors. Master transcriptional
regulatory factors such as CBF and CSL clearly play important roles in cancer cell biology.
Numerous studies show that inhibiting their function results in cancer cell death or loss of
malignancy. These may be particularly useful targets in prostate cancers as the pathways in‐
tersect and CBF enhances AR function. In the case of CBF, it may make sense to target CBFβ
to inhibit CBF activity in cancers since the activity of CBF is clearly oncogenic, while indi‐
vidual RUNX proteins can act either as oncogenes or tumor suppressors [10]. Developing
inhibitors against these key transcriptional regulators will allow their use not only for thera‐
py but also as probes to understand specific transcriptional pathways that support cancer
growth, proliferation and metastasis.
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